Cyclophosphamide And Doxorubicin (4 VS 6 Cycles) Versus Paclitaxel (4 VS 6 Cycles) As Adjuvant Therapy For Breast Cancer in Women With 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial, Phase III Randomized Study.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin
- Indications Early breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- 18 May 2017 Biomarkers information updated
- 05 Jun 2013 Primary endpoint 'Relapse-free-survival-rate' has not been met.
- 04 Jun 2013 Results after a median follow-up period of 6.1 years presented at the 49th Annual Meeting of the American Society of Clinical Oncology.